Clear Scientific Reports Positive Phase 2 Results for CS-1103, the First Investigational Therapeutic That Removes Fentanyl from the Body

<p>Fentanyl Phase 2 Trial met all endpoints; Phase 3 planned for H1 2027 CAMBRIDGE, Mass., Oct. 1, 2026 /PRNewswire/ -- Clear Scientific, Inc. today announced positive top-line results from its Phase 2 trial of CS-1103, a small-molecule sequestrant that immediately binds and inactivates...</p>